An enzyme-linked immunosorbent assay (ELISA) for the measurement of antibodies to different parts of the gram-negative lipopolysaccharide core region

Bovine serum albumin was complexed with the core antigens of either Escherichia coli J5 LPS, Salmonella minnesota R595 LPS or E. coli lipid A. These core-BSA complexes were used for solid-phase coating in ELISAs for anti-core antibodies. Antibodies, binding to various parts of the core region were easily quantified in a single experimental set-up, which was hitherto not possible. The ELISA has only 3 incubation steps and is not costly as only moderate amounts of the core antigens (i.e., 1 microgram per test) were needed for coating. The sensitivity proved to be excellent and the complexes were biologically fully active (compared to native, smooth LPS), which make them suitable for the screening (after fusion) of monoclonal anti-core antibodies. Another possible application is the large-scale screening of blood-bank sera in order to find samples with a high anti-core antibody content.     

采用微孔聚丙烯纤维材料的“四川联大Ⅰ型”管外流式(ELF)中空纤维膜式氧合器的研制

介绍了“四川联大Ⅰ型”（以下简称：ＳＵＵⅠ）管外流式（ＥＬＦ）中空纤维膜式氧合器的研制、设计、外形制做及离心封端等过程，重点介绍了中空纤维膜材料选择，膜肺离心封端的原理、材料、设备及方法，并对聚氨酯胶进行离心封端的具体步聚作了较详细的叙述。作者根据自身在国外与国内的研制经验，认为离心封端的关键在于：（１）中空纤维膜材料的质量及成束质量；（２）聚氨酯封端胶材料固化特性的掌握及料量计算；（３）反应温度控制；（４）气体排除；（５）转速的控制；（６）纤维束的安装；（７）脱模和切头的时间掌握等方面。作者用外购的材料和自己设计制造的离心封端机成功地制造了我国第一个管外流式（ＥＬＦ）中空纤维成人氧合器。ＳＵＵⅠ膜式氧合器的设计是作者在国外建立的交叉流式膜肺Ｏ２、ＣＯ２传递模型的具体应用。     

一次性注射器填充级HDPE专用料的研制

通过对母料载体树脂的筛选,无机填料的选择,添加性能优良的耐辐射助剂,制成了具有耐辐射性能、加工性能良好的母料,该母料的制备工艺简单。本文所述的填充级HDPE专用料是将HDPE与填充母料经过简单掺混制成的。经测试专用料满足国家医药标准YY 0114—93《医用输液、输血、注射器聚乙烯专用料》的要求。制品厂试验表明:该填充级的HDPE专用料加工性能良好,用该填充级HDPE专用料注射成型的注射器芯杆装配成一次性注射器满足国家专业标准ZBC 31009—87《一次性无菌注射器》的要求。该填充母料的加入可大大降低材料的成本,100份HDPE 7006A可添加67份填充母料,该填充级专用料的价格比HDPE树脂降低约1500元/吨,因此该填充级HDPE专用料的推广和使用具有良好的经济效益。     

In vitro histamine release induced by radiocontrast media and various chemical analogs in reactor and control subjects

The factors governing in vitro basophil histamine release induced by radiocontrast material (RCM) were evaluated by the use of two RCMs (diatrizoate and metrizamide) and three structural analogs of RCM (benzoic acid, diaminobenzoic acid, and 3-acetamidobenzoic acid) in basophil histamine-release studies. Diatrizoate was chosen because it is a commonly used RCM and is routinely administered as a hypertonic drug (958 mOsm/kg or greater). Metrizamide is a newly synthesized RCM and is routinely administered in isotonic form (approximately 280 mOsm/kg). The analogs were used in hope of identifying any structure-function relationship that might exist between RCMs and the activation of a proposed basophil membrane receptor responsible for the induction of de granulation. In addition, results in a control group of normal subjects were compared with those in a group of patients who had experienced anaphylactoid reactions to intravenous RCM. Basophils from both groups were incubated with diatrizoate and metrizamide to assess their relative sensitivity to these drugs. Both metrizamide and diatrizoate induced in vitro histamine release. Therefore hypertonicity is not an absolute requirement for RCM-induced in vitro basophil de granulation. Although there was a trend far reagents without a prosthetic group at position 5 on the benzene ring (especially 3-acetamidobenzoic acid) to induce more release of histamine than reagents with such a prosthetic group, differences between these reagents did not reach statistical significance. Therefore no clearcut structure-function relationship could be demonstrated. “Reactor” subjects released significantly-larger percents of their intracellular histamine than did “nonreactors” (p < 0.05). Degranulated cells retained their ability to exclude trypan blue, an observation suggesting that RCM-induced histamine release does not involve cell death.     

Mechanisms of the CYNAP phenomenon: evidence in the Bw49/Bw50 model for epitopes with different spatial orientation of antibody

The mechanism of the cytotoxic-negative, absorption-positive (CYNAP) phenomenon was studied using the model of the Bw49/Bw50 split of the BW21 antigen. Anti-Bw49 antibody bound 60% as well to Bw 50 as to Bw49 cells; however, even at a cytotoxic titer of 64 against Bw49 cells, the antibody was not cytotoxic to Bw50 Cells. At equal numbers of antibody molecules bound, the anti-Bw49 antibody activated C4 and C3, and induced lysis for Bw49 but not for the Bw50 cells. These data are consistent with a model in which different spatial orientations for shared epitopes can account for CYNAP reactivity for at least some selected Bw4/Bw6-associated splits of B locus antigens.     

Factors affecting the size of the detour effect in the kinaesthetic perception of Euclidean distance

Three experiments investigated the mechanisms by which we estimate Euclidean distances on the basis of kinaesthetic cues. In all experiments, blindfolded participants followed straight and curvilinear paths with a stylus. Then, with a straight response movement, they estimated the distance between the end-points of the previously explored path. Experiment 1 was designed to validate the hypothesis—made on the basis of results from a previous study—that errors in the kinaesthetic estimations of distances (detour effect) originate from the difficulty to decompose the displacement vector into relevant and irrelevant components, which would become more severe at points of inflection. Using elliptic paths (no inflections), we demonstrated that errors are indeed reduced considerably. The role of the orientation of the work plane was investigated in Experiment 2 in which the same paths used in our previous study were oriented in the frontal rather than the horizontal plane. The results indicate that the detour effect is independent of the orientation. Moreover, despite the asymmetry that gravity introduces between upward and downward movements, errors in the two directions are almost identical. Experiment 3 addressed two issues. First, we demonstrated that introducing a delay between the exploration of the path and the response did not alter significantly the pattern of errors. By contrast, we demonstrated that errors are severely reduced when the number of paths to be explored is reduced by half. The results of the three experiments are discussed within the context of current theories of sensori-motor coding.     

不同跟腱修复材料特性的临床意义

目的　跟腱断裂术后制动弊端多 ,而早期功能锻炼优点明确 ,探讨各种缝合材料在打结后材料力学特性及滑结情况 ,为临床创新设计 ,术后无须制动的缝合组合提供依据。方法　将不同型号薇乔线 (CV)、慕丝线 (Mersilk)、攀状尼龙线 (Nylon)、普迪思 (PDS)各 1 6条剪断后各打 4个结 ,进行材料力学特性测试。结果　缝合材料的最大载荷、刚度、强度、比能分别为 :PDS >CV >Nylon >Mersilk(P <0 .0 5 )。结论　尽管PDS肌腱缝合线易滑结 ,但 1 0 -PDS ,1 0 -CV、1 0Nylon作端对端跟腱修复强度足够 ,相应 5 0PDS、5 0CV缝合材料作腱周修复也可选择 ,且打 4个以上结可靠。尽管Mersilk不易滑结 ,但不适合跟腱修复。不过好的缝合材料应选择最佳的缝合方法才更有临床意义     

异种骨内固定器力学性能的实验研究

目的了解牛骨材料及其构件的力学强度[抗拉、抗压、抗折(弯曲)和抗扭(剪切)强度].方法将材料分为天然、处理和构件(即产品)三组并制成标准试件,用规定设备按标准方法进行检测.结果(1)牦牛股骨拉伸、压缩、抗折、扭转极限应力分别为106.35±3.45、127.60±2.65、225.9±4.1、53.45±1.55(MPa),胫骨拉伸、压缩、抗折、扭转极限应力分别为114.96±1.46、184.75±3.25、211.35±2.45、51.9±0.5(MPa).湖区水牛胫骨拉伸、压缩、抗折、扭转极限应力分别为1 28.1±11、195.8±9.4、167.4±1 2.7、54.25±0.75(MPa).(2)E0气薰灭菌对牛骨材料的力学性能无明显影响,幅照灭菌对牛骨材料的力学性能稍有影响.(3)处理后,牛骨螺钉、圆钉的抗折强度较材料有所降低,而抗拉强度、抗压强度、抗扭强度变化不大.结论牛骨是一种力学性能良好,适合制作内固定构件的高强度生物材料.     

Laboratory compliance with federal government and professional society recommendations

Quality assurance issues have assumed growing importance in the cytology laboratory. The 1988 Clinical Laboratories Improvement Amendment (CLIA '88) (United States Department of Health and Human Services, Federal Register: U.S. Government Printing Office 1990;55:9495) regulates the patient identifiers and clinical data on the requisition form but does not mandate physician compliance to provide the information. We investigated the use of patient identifiers and clinical data by laboratories as specimen acceptance/rejection criteria. We surveyed 81 board certified cytopathologists and 235 randomly selected cytology laboratories for acceptance criteria of cytology specimens and received responses from 104. Approximately two thirds of all responding laboratories had specific criteria for rejecting specimens on the basis of inadequate identification or clinical data. While the vast majority required the specimens to be identified with patient name, collection date, and specimen source, a minority of laboratories required clinical information such as LMP, prior atypical cytologic/histologic specimens, and history of previous therapy. Little correlation was found between practice setting and the use of rejection criteria. Diagn Cytopathol 1994; 11:85–92. © 1994 Wiley-Liss, Inc.